Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people
N E M Jaspers(Heidelberg University), Jannick A N Dorresteijn(Utrecht University)
Cited by 118
Related Papers
Estimating treatment effects for individual patients based on the results of randomised clinical trials
|BMJ|2011|178
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease
|Journal of the American College of Cardiology|2023|134
C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations
|The American Journal of Cardiology|2023|66
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials
|Atherosclerosis|2024|36
Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease
|International Journal of Cardiology|2023|23